Johann S de Bono Selected Research

Hyperglycemia

9/2017	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
11/2014	Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
1/2014	Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
10/2013	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
12/2011	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
3/2010	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
10/2007	Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johann S de Bono Research Topics

Disease

177	Prostatic Neoplasms (Prostate Cancer) 09/2022 - 12/2005
114	Neoplasms (Cancer) 09/2022 - 01/2002
23	Circulating Neoplastic Cells 05/2021 - 06/2007
22	Disease Progression 09/2022 - 08/2009
19	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2009
19	Fatigue 11/2020 - 05/2006
11	Nausea 01/2022 - 10/2007
10	Pain (Aches) 01/2020 - 09/2012
9	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 05/2010
8	Hypertension (High Blood Pressure) 01/2022 - 04/2008
8	Diarrhea 04/2020 - 10/2007
8	Carcinogenesis 09/2016 - 08/2009
7	Vomiting 04/2020 - 04/2008
7	Hyperglycemia 09/2017 - 10/2007
6	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2003
5	Genomic Instability 01/2021 - 01/2010
5	Exanthema (Rash) 11/2020 - 12/2011
5	Hypokalemia 10/2013 - 10/2008
4	Thrombocytopenia (Thrombopenia) 01/2022 - 10/2013
4	Neutropenia 01/2022 - 09/2011
4	Adenocarcinoma 01/2022 - 11/2004
4	Carcinoma (Carcinomatosis) 01/2022 - 06/2007
4	Melanoma (Melanoma, Malignant) 10/2017 - 02/2007
3	Triple Negative Breast Neoplasms 01/2022 - 12/2011
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 01/2002
3	Cancer Pain 01/2017 - 01/2013
3	Stomatitis 02/2015 - 12/2011
3	Anorexia 03/2010 - 10/2007
2	Ataxia Telangiectasia (Louis Bar Syndrome) 04/2022 - 01/2021
2	Lymphoma (Lymphomas) 01/2022 - 12/2011
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

43	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 08/2008
40	Biomarkers (Surrogate Marker)IBA 04/2022 - 06/2007
32	Abiraterone AcetateIBA 01/2022 - 10/2008
32	Pharmaceutical PreparationsIBA 01/2022 - 04/2008
32	abirateroneIBA 01/2022 - 11/2008
30	enzalutamideIBA 03/2022 - 12/2009
29	Docetaxel (Taxotere)FDA Link 01/2022 - 03/2010
26	AndrogensIBA 01/2022 - 08/2008
21	Hormones (Hormone)IBA 01/2022 - 06/2007
21	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 04/2009
20	Prednisone (Sone)FDA LinkGeneric 01/2022 - 03/2010
18	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021 - 01/2010
17	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2008
10	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021 - 07/2009
10	olaparibIBA 10/2020 - 07/2009
9	LigandsIBA 01/2022 - 10/2008
9	PlatinumIBA 01/2020 - 05/2010
8	Biological ProductsIBA 01/2021 - 02/2007
7	taxaneIBA 10/2021 - 10/2003
7	Monoclonal AntibodiesIBA 01/2014 - 11/2004
7	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 04/2011 - 08/2008
6	AntigensIBA 09/2022 - 12/2011
6	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 12/2011
6	Cell-Free Nucleic AcidsIBA 12/2018 - 01/2012
5	Messenger RNA (mRNA)IBA 01/2022 - 11/2012
5	cabazitaxel FDA Link 01/2022 - 06/2011
5	Phosphotransferases (Kinase)IBA 01/2020 - 09/2010
5	Testosterone (Sustanon)FDA Link 01/2019 - 08/2008
5	Insulin-Like PeptidesIBA 01/2014 - 06/2007
5	figitumumabIBA 01/2014 - 06/2007
4	RNA (Ribonucleic Acid)IBA 04/2022 - 01/2003
4	Prednisolone (Predate)FDA LinkGeneric 01/2022 - 01/2017
4	SteroidsIBA 01/2022 - 12/2005
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2020 - 02/2015
4	cabozantinibIBA 01/2020 - 10/2014
4	Alkaline PhosphataseIBA 01/2020 - 04/2008
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2015 - 01/2002
4	MK 2206IBA 02/2015 - 12/2011
3	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 05/2015
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2018
3	EnzymesIBA 01/2021 - 01/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 01/2014
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 11/2014
3	Narcotics (Narcotic Analgesics)IBA 01/2019 - 10/2014
3	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2019 - 01/2015
3	Amino Acids FDA Link 10/2017 - 11/2015
3	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 09/2016 - 07/2009
3	Androgen Antagonists (Antiandrogens)IBA 01/2015 - 01/2011
3	Histone Deacetylase InhibitorsIBA 10/2013 - 10/2008
3	MineralocorticoidsIBA 05/2011 - 10/2008
3	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 03/2010 - 10/2007
2	Folic Acid (Vitamin M)FDA LinkGeneric 09/2022 - 10/2019
2	TensinsIBA 04/2022 - 12/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 04/2022 - 12/2011
2	vistusertibIBA 01/2022 - 08/2015
2	pulrodemstat besilateIBA 01/2022 - 01/2021
2	molibresibIBA 01/2022 - 04/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2007
2	Nuclear Proteins (Protein, Nuclear)IBA 01/2022 - 04/2020
2	Lysine (L-Lysine)FDA Link 01/2022 - 01/2021
2	CytokinesIBA 01/2022 - 05/2006

Therapy/Procedure

135	Castration 09/2022 - 08/2008
75	Therapeutics 01/2022 - 01/2002
40	Drug Therapy (Chemotherapy) 09/2022 - 06/2007
8	Radiotherapy 01/2022 - 05/2013
7	Precision Medicine 09/2022 - 09/2009
3	Aftercare (After-Treatment) 01/2019 - 01/2017
2	Drug Tapering 01/2022 - 10/2013